News

search close

Relmada Therapeutics Receives FDA Fast Track Designation for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder

Read more

Relmada Therapeutics to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022

Read more

Relmada Therapeutics Appoints Biopharmaceutical Marketing and Commercial Planning Veteran John Hixon as Head of Commercial

Read more

Relmada Therapeutics to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference

Read more

Relmada Therapeutics to Participate in the 2022 Jefferies Global Healthcare Conference

Read more

Relmada Therapeutics to Present Data at the American Society of Clinical Psychopharmacology 2022 Annual Meeting

Read more

Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

Read more

Relmada Therapeutics Announces Publication of REL-1017 Preclinical Data in Frontiers in Pharmacology

Read more

Relmada Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022

Read more

Relmada Therapeutics to Present Data at the Ketamine & Related Compounds International Hybrid Conference 2022

Read more